The announcement of a significant net product revenue of $50.7 million for the year is a positive indicator of Krystal Biotech's financial health and operational success. This performance is likely to be viewed favorably by investors, potentially leading to a positive short-term impact on KRYS's stock price. The substantial revenue figure suggests that the company is effectively monetizing its products, which is a critical factor for growth and stability in the biotech industry.